Celcuity (NASDAQ:CELC) Announces Quarterly Earnings Results

Celcuity (NASDAQ:CELC) announced its quarterly earnings results on Thursday. The company reported ($1.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.30, FiscalAI reports.

Here are the key takeaways from Celcuity’s conference call:

• Commercial launch of REVTORPYK is off to a strong early start: within about a month of availability, 78% of Celcuity’s 36 priority accounts had ordered the drug, and 91% of U.S. commercial and Medicare lives were covered. The company also reported a preferred NCCN recommendation and inclusion in three of four major provider pathways.
• VIKTORIA-1 results presented at ESMO showed encouraging efficacy across patient subgroups, including median progression-free survival of 21.5 months for the triplet in patients without liver metastases, and higher response rates than the comparator. Celcuity also highlighted lower treatment-discontinuation rates with gedatolisib regimens, while noting the results are from clinical trials.
• Potential growth extends beyond the current second-line indication: Celcuity expects to submit data for the PIK3CA-mutant cohort to global regulators, is conducting first-line breast cancer trials, and plans a randomized phase II prostate cancer study in the first half of 2027. These programs remain subject to clinical and regulatory outcomes.
• Third-quarter net loss widened to $73.3 million from $43.8 million a year earlier as operating expenses rose, largely reflecting commercial launch investment. Celcuity ended the quarter with $642.7 million in cash, equivalents and short-term investments and said it expects funding through 2029; it reported no product revenue in the quarter.

Celcuity Stock Up 4.3%

Shares of CELC traded up $2.75 during mid-day trading on Friday, hitting $66.79. 1,081,623 shares of the company’s stock were exchanged, compared to its average volume of 1,806,096. The company has a market cap of $3.27 billion, a PE ratio of -14.18 and a beta of 0.16. Celcuity has a 52 week low of $53.54 and a 52 week high of $151.02. The company has a 50-day simple moving average of $75.11 and a 200 day simple moving average of $99.38. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CELC. Craig Hallum restated a “buy” rating and set a $178.00 price objective on shares of Celcuity in a report on Wednesday, July 15th. Stifel Nicolaus reduced their target price on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Citigroup reiterated a “market outperform” rating on shares of Celcuity in a report on Monday, October 19th. Needham & Company LLC dropped their price target on Celcuity from $140.00 to $134.00 and set a “buy” rating on the stock in a research note on Wednesday, September 30th. Finally, Wall Street Zen downgraded Celcuity from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Celcuity currently has an average rating of “Moderate Buy” and an average price target of $152.14.

Key Stories Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity reported a third-quarter loss of $1.21 per share, narrower than analysts’ expected loss of $1.51. The earnings beat may support sentiment. MarketBeat earnings report
• Positive Sentiment: The Q3 earnings-call summary highlighted strong launch momentum for Revtorpic, a potential positive commercial catalyst. Q3 2026 earnings-call highlights
• Positive Sentiment: Guggenheim kept its Buy rating and lowered its price target only modestly, from $171 to $169; the report cited substantial upside relative to the referenced share price. TickerReport article
• Negative Sentiment: Celcuity’s Q3 adjusted loss widened, a counterpoint to the per-share earnings beat and a reminder that the company remains loss-making. Celcuity Q3 adjusted loss widens

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.